The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the alpha4beta1 integrin on mesenchymal stem cells and for the surface of bone.

The present invention concerns conjugate compounds comprising a bisphosphonate covalently bonded to a prostatic acid phosphatase inhibitor and compositions comprising such conjugates. Methods for treating and inhibiting prostate cancer bone metastases, and determining whether a conjugate is useful for such treatment are also provided. In some instances, the bisphosphonate is alendronate, and it is covalently bonded to either tartaric acid or glyceric acid.

The present invention relates to a new diphosphonate compound, and the method to prepare the above new diphosphonate compound. The new diphosphonate compound provided in this present invention exhibits an activity in inhibiting osteoclast equivalent to alendronate sodium, and a higer activity in affecting the proliferation of osteoplast than the positive control compounds, but the positive control exhibits a weaker effect on osteoblast proliferation. In experimental examples, an administration s...

FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, namely nephrology, and may be used for administering alendronate as an agent for low-turnover metabolic bone disease in the patients suffering chronic renal insufficiency (CRI).EFFECT: invention provides preventing developing incurable adynamic bone disease and transforming the low-turnover metabolic bone disease into the high-turnover metabolic bone disease thereby reducing the risks of fractures and a cardiovascular pathol...

The present disclosure relates to a new diphosphonate compound, and the method to prepare the above new diphosphonate compound. The new diphosphonate compound exhibits an activity in inhibiting osteoclast equivalent to alendronate sodium, and a higher activity in affecting the proliferation of osteoplast than the positive control compounds, but the positive control exhibits a weaker effect on osteoblast proliferation. In experimental examples, an administration schedule for the diphosphonate com...

The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the a4ss1 integrin on mesenchymal stem cells and for the surface of bone.